113 results about "TAZOBACTAM SODIUM" patented technology

The invention relates to a high-purity tazobactam sodium compound, and particularly provides a method for refining the tazobactam sodium compound. The method comprises the following steps: a, dissolving a tazobactam sodium coarse product into water, regulating the pH value of aqueous solution to less than 7 and collecting solid precipitated from the solution; b, dissolving the solid obtained in the step a into organic solvent to obtain solution to be refined; c, putting the solution to be refined into macroporous absorption resin, performing elution and purification by using eluting agent, and collecting eluent; and d, regulating the pH value of the eluent obtained in the step c to 7 and collecting the precipitated solid to obtain refined tazobactam sodium. The refined tazobactam sodium compound prepared by the method has the purity of over 99.8 percent and the yield of over 90 percent.

The invention provides a method for preparing a high purity drug, particularly relating to a method for preparing high purity cefoperazone sodium or tazobactam sodium. The invention also provides a method for preparing a compound powder-injection of high purity cefoperazone sodium and high purity tazobactam sodium and the high purity drug or high purity drug compound prepared according to the methods.

The invention discloses a compound preparation of piperacillin sodium and tazobactam sodium for injection, which comprises piperacillin sodium and tazobactam sodium by the weight ratio of 3-4:0.8-1.2. The preparation can be used for treating respiratory system infection, urological infection, otologia infection and skin infection.

The invention discloses a suspension powder injection with a cefoperazone sodium and tazobactam sodium pharmaceutical composition as an active ingredient, and comprises the following components: 4 parts of the cefoperazone sodium, 1 part of the tazobactam sodium, 5-30 parts of an emulsifier, 1-15 parts of an auxiliary emulsifier and 1-40 parts of a freeze-drying support agent. The invention further discloses an application thereof in preparing medicines for treating cystitis.

The invention relates to a mezlocillin sodium compound which is determined by adopting X-ray powder diffraction and has characteristic peaks shown in 2theta of 8.9, 15.7, 16.5, 18.9, 19.8, 24.6, 26.4, 27.8, 29.0, 29.7, 31.8, 33.2, 34.7, 36.8, 37.5, 38.9 and 40.1 in a map. The invention also relates to a mezlocillin sodium compound and a medicine composition with a medicine active component of the mezlocillin sodium compound or the mezlocillin sodium compound and sulbactam sodium or tazobactam sodium. The medicine composition is a powder injection of the mezlocillin sodium compound, or a medicine mixture powder injection of the mezlocillin sodium compound and the sulbactam sodium or tazobactam sodium. The mezlocillin sodium compound has the advantages of difficulty in absorbing mixture, good flowability, high dissolving speed, kept extremely high stability, and greatly improved convenience and safety of the mezlocillin sodium.

The invention discloses a suspension powder injection of a piperacillin sodium and tazobactam sodium pharmaceutical composition, and further discloses an application thereof to preparing medicines for treating lung abscess.

The invention relates to a medicinal composition of cefoperazone sodium and tazobactam sodium. The medicinal composition comprises the following components in part by weight: 4 to 8 parts of cefoperazone sodium and 1 part of tazobactam sodium, wherein the tazobactam sodium is measured by a powder X-ray diffraction measuring method, and characteristic diffraction peaks are shown at the positions of 6.9 degrees, 10.5 degrees, 11.4 degrees, 16.6 degrees, 19.2 degrees, 22.7 degrees, 27.0 degrees, 29.7 degrees and 33.5 degrees in an X-ray powder diffraction map expressed by a diffraction angle of between 2 theta+/-0.2 degree. The medicinal composition has the advantages of high stability, low relevant substance content, controllable quality and the like, and the administration safety of patients is improved. The invention also relates to a method for preparing the tazobactam sodium with the technical characteristics of the characteristic diffraction peaks.

The invention discloses a composite pharmaceutical composition of cefoperazone sodium and tazobactam sodium. The composite pharmaceutical composition is an injection, and is prepared from the following components in parts by weight: 3.5-4.5 parts of cefoperazone sodium, 1 part of tazobactam sodium, 0.5-1 part of ambroxol hydrochloride, 0-6 parts of excipient, 0-10 parts of isotonic agent, 0-1 part of antioxidant, a proper amount of citric acid-sodium citrate and 20 parts of injection water. The composite preparation of the cefoperazone sodium and the tazobactam sodium disclosed by the invention is stable in quality and significant in curative effect, not only can three active ingredients be evenly mixed, but also the composite pharmaceutical composition is excellent in stability, good in solubleness and good in clinical use safety.

The invention provides a preparation method for injection cefoperazone sodium tazobactam sodium composition. The preparation method comprises the following steps of: crushing the cefoperazone sodium and the tazobactam sodium; and mixing the cefoperazone sodium and the tazobactam sodium in a weight ratio of 4:1; and separately packaging, pressing and capping the mixture. The preparation method is characterized in that the fineness of pulverization of the cefoperazone sodium and the tazobactam sodium is 50-120 meshes.

The invention discloses a piperacillin sodium and tazobactam sodium pharmaceutical composition and a preparation method thereof. The pharmaceutical composition mainly comprises piperacillin sodium and tazobactam sodium, as well as a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer pair, and the powder injection is prepared by spraying and drying. The disodium hydrogen phosphate-sodium dihydrogen phosphate buffer pair is adopted for playing a role in buffering the pH of a solution, thus ensuring the content stability of piperacillin sodium, and no generation of carbon dioxide; the preparation technology is simple, convenient to control, fast to dry, and applicable to continuous large-scale production. The piperacillin sodium and tazobactam sodium powder injection is fast to dissolve, stable in quality, free from crystallization and degradation products, and the solution clarity meets the specification.

The invention discloses a preparation method of piperacillin sodium and tazobactam sodium for injection. The preparation method comprises the following steps: adding water into a blending tank, cooling to 5-10 DEG C, adding citric acid, then slowly adding sodium bicarbonate, and after reacting, reading the pH value and adjusting the pH value to be 6.3-6.6; adding piperacillin acid into the blending tank, and then dropwise adding the sodium bicarbonate solution, wherein the pH value in the dropwise adding process is controlled to be less than or equal to 7.0; after dropwise adding, adding tazobactam acid, and then dropwise adding the sodium bicarbonate solution, wherein the pH value in the dropwise adding process is controlled to be less than or equal to 7.0; after dropwise adding, carrying out vacuum removal on carbon dioxide gas by suction, and after the feed liquid in the blending tank is stabilized, reading the pH value and adjusting the pH value to be 6.0-6.5; and carrying out aseptic filtration and freeze-drying to obtain raw powder of piperacillin sodium and tazobactam sodium for injection. According to the preparation method, by adding salified citric acid, the acidity stability of the product is increased, the decomposition of piperacillin sodium and tazobactam sodium is inhibited, and the storage stability of the product is increased.

The invention relates to a novel high performance liquid chromatogram (HPLC) method, which can simultaneously detect the content of two single ingredients and relevant impurities in the cefotaxime sodium tazobactam sodium compound. The two ingredients have no interferences or influences. The method has easy operation, strong specificity, high sensitivity, large linear range and good stability, and can be used for detecting a compound preparation and raw materials.

The invention discloses piperacillin sodium-tazobactam sodium medicinal composition microsphere injection. The injection is characterized by consisting of piperacillin sodium, tazobactam sodium, polylactic acid-polyethylene glycol (PLA-PEG), PEG600, polysorbate 80 and mannitol and particularly consisting of 4 to 8 parts of piperacillin sodium, 1 part of tazobactam sodium, 4 to 9 parts of PLA-PEG, 6 to 10 parts of PEG600, 1 to 3 parts of polysorbate 80 and 2 to 4 parts of mannitol. Compared with the prior art, the piperacillin sodium-tazobactam sodium medicinal composition microsphere injection prepared by the invention has the characteristics of good stability, high entrapment rate, high preparation technology repeatability, suitability for industrial production, uniform particle distribution, few solvent residue, good injectability and excellent sustained release property.

The invention discloses a medicine composition of piperacillin sodium tazobactam sodium and a preparation method thereof. The medicine composition is sterile powder injection, wherein the weight ratio of piperacillin sodium tazobactam sodium is (2-4):1. The piperacillin sodium tazobactam sodium sterile powder injection prepared in the invention has high stability and less impurity; by utilizing the sterile powder injection, the safety and effectiveness of clinical medication are improved greatly.

The invention discloses a production process of compound preparation of ceftriaxone sodium and tazobactam sodium for injection, comprising the steps of weighing raw materials of ceftriaxone sodium, tazobactam sodium, sterilized water for injection, mixed liquid of ethyl acetate and isopropanol, and anhydrous ethanol based on the weight ratio of 3-5:1:2:5:9; conducing dissolution and filtration; crystallizing and washing; and lyophilizing to obtain the compound preparation of ceftriaxone sodium and tazobactam sodium for injection. The invention is applicable to the compound preparation of ceftriaxone sodium and tazobactam sodium for injection, which is produced according to the ratio of 3:1-5:1 of ceftriaxone to tazobactam; and the invention adopts evenly mixing of liquid phase, can achieve good mixing uniformity, effectively increase the purity of the preparations simultaneously, and further guarantee the advantage of high safety of clinic use.

The invention belongs to the technical field of medicines and in particular relates to a drug composition of cefoperazone sodium and tazobactam sodium and a preparation method thereof. The drug composition is sterile powder injection. The mass ratio of cefoperazone sodium to tazobactam sodium in the drug composition is (4-8):1, wherein cefoperazone sodium is shown in a drawing 1, an X-ray powder diffraction pattern obtained by powder X-ray diffractometry and the chemical structural formula of cefoperazone sodium is shown in the formula (I) in the specification. Compared with the prior art, the cefoperazone sodium compound used in the drug composition has lower hygroscopicity and good thermal stability, thus improving the stability of the drug composition of cefoperazone sodium and tazobactam sodium and reducing the impurity content.

The invention provides a combined medicament, in particular a meropenem tazobactam sodium combined medicament for treating infectious diseases caused by acinetobacter baumannii. The meropenem and tazobactam sodium combined medicament has a synergistic effect and an accumulative antibacterial effect on the infectious diseases caused by the acinetobacter baumannii and particularly has a good synergistic effect and a good accumulative antibacterial effect on multiple medicine-tolerant acinetobacter baumannii strains, and can be used for curing clinical infection caused by the multiple medicine-tolerant acinetobacter baumannii strains in clinic.

The invention provides a beta-lactam compound antibiotic composition, which contains cefuroxime and a tazobactam sodium monohydrate, or cefuroxime salts and the tazobactam sodium monohydrate, wherein the weight ratio of the cefuroxime salts counted according to the cefuroxime to the tazobactam sodium monohydrate counted according to the tazobactam is (1-8):1. The beta-lactam compound antibiotic composition disclosed by the invention is used for being prepared into a clinically-acceptable medicinal preparation with the cefuroxime and salts thereof as well as the tazobactam sodium monohydrate as active components. According to the beta-lactam compound antibiotic composition, the tazobactam sodium monohydrate is mixed with the cefuroxime and salts thereof so as to improve the flowability of composition powder, enable the uniformity of the medicament to be better in the production process and improve the yield of the product; and the beta-lactam compound antibiotic composition has saved production cost and is especially suitable for popularization and application.

The invention discloses a liposome injection prepared from ceftriaxone sodium tazobactam sodium medicinal composition, comprising the following components in parts by weight: 3 parts of ceftriaxone sodium, 1 part of azobactam sodium, 3-18 parts of liposome film material, 1.2-10 parts of addictive, 6-25 parts of frozen-dried support agent and 0.1-4 parts of antioxidant. By preparing the ceftriaxone sodium tazobactam sodium medicinal composition into liposome, the stability of a preparation can be greatly improved, the quality of medicines is improved, the toxic or side effects are reduced, the target property can be acquired and the curative effect can be improved.

The invention relates to a pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry. Every 100 g of the pharmaceutical composition comprises 2 to 10 g of ceftiofur hydrochloride, 0.25 to 10 g of tazobactam sodium, 5 to 10 g of probenecid sodium, 0.1 to 0.5 g of dexamethasone sodium phosphate and 2 to 15 g of beta-cyclodextrin, with the balance being pharmaceutically acceptable accessories. The pharmaceutical composition has the advantages of reasonable composition, low cost, a remarkable curative effect on clinical pathogenic escherichia coli, especially on drug-resistant intractable escherichia coli, a simple preparation method, stable properties and convenience in large scale intensive production.